New molecular insights occasionally lead to the rapid development of therapeutic agents that improve the outcomes of patients with cancer; however, these breakthroughs can be followed by extensive, empirically driven and often unsuccessful efforts at extending the drug to other indications or combinations. Herein, we describe the clinical development of imatinib, a paradigm of rapid molecularly driven drug development, and advocate for a balanced portrayal of the potential of molecularly targeted therapies for cancer.
Your institute does not have access to this article
Open Access articles citing this article.
British Journal of Cancer Open Access 29 March 2021
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
TIME. Drugs that fight cancer. TIME http://content.time.com/time/covers/0,16641,20010528,00.html (2001).
Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935–942 (2002).
FDA. Drugs@FDA: FDA approved drug products. FDA https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588 (2018).
Yam, C. et al. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest. New Drugs 36, 1103–1109 (2018).
Carlisle, B. G. et al. Patient benefit and risk in anticancer drug development: a systematic review of the ixabepilone trial portfolio. medRxiv https://www.medrxiv.org/content/10.1101/19003467v1 (2019).
Boyiadzis, M. M. et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer 6, 35 (2018).
Walker, I. & Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15–16 (2008).
Hey, S. P., Heilig, C. M. & Weijer, C. Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials 14, 1 (2013).
The work of J.K. is funded by the Canadian Institutes of Health Research (CIHR; EOG111391). Without in any way implying endorsement of the contents of this article, the authors thank members of STREAM and H. Atkins for helpful consultations.
The authors declare no competing interests.
About this article
Cite this article
Carlisle, B.G., Zheng, T. & Kimmelman, J. Imatinib and the long tail of targeted drug development. Nat Rev Clin Oncol 17, 1–3 (2020). https://doi.org/10.1038/s41571-019-0287-0
British Journal of Cancer (2021)